320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
The Readout Loud
00:00
Intro
This chapter discusses the recent departure of a gene therapy pioneer and the closure of a gene editing startup, featuring insights from a STAT reporter on the biotech industry's evolving landscape. It wraps up with an advertisement for the 2024 STAT Summit, emphasizing its focus on innovations in health and medicine.
Transcript
Play full episode
